NASDAQ:MREO

Mereo Biopharma Group Stock Predictions

etoro logo Buy MREO
*Your capital is at risk
$0.334
-0.0052 (-1.53%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

MREO Prediction Chart

MREO Predictions History

Latest community submissions for MREO.
Predictor Target Session Target Price Result Direction Accuracy Score
Oct 1, 2025 $2.02 -1.88% $2.05 V 98.60% 2
Oct 1, 2025 $2.04 -1.17% $2.05 V 99.31% 4
Oct 1, 2025 Bullish $2.05 X 0
Sep 29, 2025 $1.90 -1.91% $1.96 X 97.09% 0
Sep 29, 2025 $1.92 -1.19% $1.96 X 97.80% 0
Sep 29, 2025 Bullish $1.96 V 1
Sep 25, 2025 $1.76 -1.96% $1.77 V 99.70% 5
Sep 25, 2025 $1.78 -1.22% $1.77 V 99.55% 5
Sep 25, 2025 Bullish $1.77 X 0
Jun 27, 2025 $2.74 -2.18% $2.66 V 97.03% 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for MREO with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT MEREO BIOPHARMA GROUP PLC
Mereo Biopharma Group
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase ...
GOLDEN STAR
Ticker Change Signal Date
RUN
$12.83
18.86% May 06
GLBE
$31.61
5.35% May 05
SAP
$172.39
10.69% May 05
W
WCLD
$27.34
27.18% Apr 29
ADBE
$243.57
7.61% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE